Advertisement

Active Surveillance for Low Risk Prostate Cancer

  • Laurence KlotzEmail author
Chapter

Abstract

There is strong evidence that low risk and many cases of low-intermediate risk prostate cancer are indolent, have little or no metastatic potential, and do not pose a threat to the patient in his lifetime (clinically insignificant). We have made major strides in understanding who these patients are, and in counseling the use of conservative management in such individuals. A key component of this approach is the early identification of those “low risk” patients who harbor higher risk disease, and are likely to benefit from definitive therapy. This represents about 30 % of newly diagnosed low risk patients. A further small proportion of patients with low risk disease demonstrate biological progression to higher grade disease. The results of active surveillance, embodying conservative management with selective delayed intervention for the subset who are re-classified as higher risk over time based on repeat biopsy, imaging, or biomarker results, have shown that this approach is safe in the intermediate to long term, with a 3 % cancer-specific mortality at 10–15 years. Further refinement of the surveillance approach is ongoing, incorporating MRI and targeted biopsies. For patients with an identifiable target, focal therapy represents a complementary approach designed to conserve tissue and quality of life which eradicating the “index,” or life-threatening lesion. Thermal ablation using focused ultrasound or interstitial laser, cryoablation, electroporation, and brachytherapy have all been applied in a focal fashion with promising results.

Keywords

Migration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167(4):1664–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force [Internet]. Rockville: Agency for Healthcare Research and Quality (US); 2011.Google Scholar
  3. 3.
    Carlsson SV, Kattan MW. Prostate cancer: personalized risk – stratified screening or abandoning it altogether? Nat Rev Clin Oncol. 2016;13(3):140–2.CrossRefPubMedGoogle Scholar
  4. 4.
    Barry MJ, Nelson JB. Patients present with more advanced prostate cancer since the USPSTF screening recommendations. J Urol. 2015;194(6):1534–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13(4):205–15.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo. 1994;8(3):439–43.PubMedGoogle Scholar
  7. 7.
    Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Sykes J, Lockwood G, van der Kwast TH. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Ahmed H, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012;13(11):e509–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Berg KD, Vainer B, Thomsen FB, Røder MA, Gerds TA, Toft BG, Brasso K, Iversen P. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol. 2014;66(5):851–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 2015;28(1):128–37.CrossRefPubMedGoogle Scholar
  13. 13.
    Serrano M. Cancer: a lower bar for senescence. Nature. 2010;464(7287):363–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Eggener S, Scardino P, Walsh P, et al. 20 year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–75.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Scott Eggener, personal communication.Google Scholar
  16. 16.
    Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) < =6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36(9):1346–52.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Haffner M, Yegasubramanian S. The clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918–22.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Barbieri CE, Demichelis F, Rubin MA. The lethal clone in prostate cancer: redefining the index. Eur Urol. 2014;66(3):395–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Zomer A, Maynard C, Verweij FJ, Kamermans A, Schäfer R, Beerling E, Schiffelers RM, de Wit E, Berenguer J, Ellenbroek SI, Wurdinger T, Pegtel DM, van Rheenen J. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 2015;161(5):1046–57.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Optimizing the definition of very low risk prostate cancer. BJU Int. 2015;116(2):213–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol. 2015;33(30):3379–85.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63:597.CrossRefPubMedGoogle Scholar
  24. 24.
    Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112(12):2664–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, Irie A, Sato T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T, Habuchi T, Fujimoto H, Niwakawa M. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol. 2008;38(2):122–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, Schröder FH. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51(5):1244–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Barayan GA, Brimo F, Bégin LR, Hanley JA, Liu Z, Kassouf W, Aprikian AG, Tanguay S. Factors influencing disease progression of prostate cancer under active surveillance: a McGill university health center cohort. BJU Int. 2014;114(6b):E99–104.CrossRefPubMedGoogle Scholar
  28. 28.
    Rubio-Briones J, Iborra I, Ramírez M, Calatrava A, Collado A, Casanova J, Domínguez-Escrig J, Gómez-Ferrer A, Ricós JV, Monrós JL, Dumont R, López-Guerrero JA, Salas D, Solsona E. Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know. Actas Urol Esp. 2014;38(9):559–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol. 2013;63(1):101–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Thomsen FB, Røder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J. 2013;60(2):A4575.PubMedGoogle Scholar
  31. 31.
    Selvadurai ED, Singhera M, Thomas K, Mohammed K, Woode-Amissah R, Horwich A, Huddart RA, Dearnaley DP, Parker CC. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol. 2013;64:981–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013;31(24):2991–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Cuzick J, Berney DM, Fisher G, the Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death on conservatively managed needle biopsy cohort. Br J Cancer. 2012;106:1095–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D, Maggrah A, Klotz L, Parr RL, Dakubo GD. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis. 2013;16(4):398.CrossRefGoogle Scholar
  36. 36.
    Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373–80.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS, Shukla-Dave A, Eastham J, Scardino P, Hricak H. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol. 2012;188(5):1732–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, Gallucci M, Tombolini V, Gentile V, Catalano C. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol. 2015;33(1):17.e1–7.CrossRefGoogle Scholar
  39. 39.
    Popiolek M, Rider JR, Andrén O, Andersson SO, Holmberg L, Adami HO, Johansson JE. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63(3):428–35.CrossRefPubMedGoogle Scholar
  40. 40.
    Yamamoto T, Musunuru B, Vesprini D, Zhang L, Ghanem G, Loblaw A, Klotz L. Metastatic prostate cancer in men initially treated with active surveillance. J Urol. 2016;195(5):1409–14. pii: S0022-5347(15)05445-2.CrossRefPubMedGoogle Scholar
  41. 41.
    Vickers A. Systematic review of pretreatment PSA velocity and doubling time as PCA predictors. J Clin Oncol. 2008;27:398–403.CrossRefPubMedGoogle Scholar
  42. 42.
    Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D, Klotz L. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol. 2010;184(5):1942–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Division of UrologySunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations